Revvity (RVTY)

Equity

Sell: $102.47|Buy: $117.52|Change: 0.31 (0.29%)

Open

$106.43

Previous close

$108.49

Trade high

$108.85

Volume

1,551,957

Year high

$126.57

Year low

$81.36

Dividend yield

0.26%

Market capitalisation

$12.34 bn

P/E ratio

56.08

ISIN

US7140461093

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Dividends

	Previous	Latest
Record date	16/01/2026	17/04/2026
Ex-dividend date	16/01/2026	17/04/2026
Payment date	06/02/2026	08/05/2026
Amount	$0.07	$0.07

Performance 30/01/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Revvity	+ 0.29
More...

Company profile

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.